Global Focus on Improved Outcomes: Global Cardiopulmonary Bypass System Market
The cardiopulmonary bypass systems market is on track for substantial growth over the next decade. In 2018, the total net worth of cardiopulmonary bypass systems sold globally was estimated at USD 173.9 million. By 2023, this figure had risen to USD 197.3 million, with further projections indicating a steady increase.
According to recent forecasts, the global cardiopulmonary bypass system market is anticipated to reach USD 270.9 million by 2033. This growth trajectory represents a compound annual growth rate (CAGR) of 3.2% during the forecast period.
It is anticipated that the rising costs of treating serious illnesses, such as heart ailments, will result in a greater need for cardiopulmonary bypass equipment. It is anticipated, therefore, that the adverse effects of bypass surgery will impede the uptake of these devices. Conversely, it is expected that the rapid progress of technology and the increase in surgical procedures will propel market expansion and offer new opportunities to market players.
Your Insightful Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-5855
The rising prevalence of cardiovascular diseases, coupled with advancements in medical technology, is driving the demand for cardiopulmonary bypass systems. These systems play a critical role in cardiac surgeries, providing essential support to patients during procedures.
As the market continues to expand, healthcare providers and patients alike stand to benefit from improved access to innovative cardiopulmonary bypass technologies, ultimately leading to better patient outcomes and enhanced quality of care.
Supporting Heart Health: Cardiopulmonary Bypass Systems Play a Vital Role
The global cardiopulmonary bypass system market is experiencing continued growth, driven by the increasing need for effective tools in cardiac surgery. Cardiopulmonary bypass systems play a critical role in open-heart surgery by temporarily taking over the functions of the heart and lungs, allowing surgeons to operate on a still heart.
Market Growth Fueled by Multiple Factors:
Several factors are contributing to the growth of the cardiopulmonary bypass system market:
Increased Focus on Cardiac Care: Rising healthcare expenditure directed towards combating heart disease, a leading global health concern, is creating a greater demand for advanced cardiac surgical procedures.
Technological Advancements: The market is continuously evolving with the development of innovative bypass systems. Roller pumps, for example, are gaining traction due to their affordability, ease of use, and reliable flow management.
Expanding Surgical Needs: The growing number of lung transplant procedures, particularly en-bloc double-lung transplants, is driving the demand for cardiopulmonary bypass systems to support these complex surgeries.
Key Takeaways:
The global cardiopulmonary bypass system market is expected to reach US$270.9 million by 2033, reflecting a rise from US$197.3 million in 2023.
This growth is projected at a steady compound annual growth rate (CAGR) of 3.2% throughout the forecast period.
Rising healthcare spending on cardiac procedures and advancements in technology are key drivers for market expansion.
The Cardiopulmonary Bypass System Market:
Minnetronix Inc.
Transonic
MAQUET Holding B.V. & Co. KG.
Getinge AB
Terumo Corporation
MicroPort Scientific Corporation
Xenios AG
Nipro Corporation
Eurosets Srl
OriGen Biomedical
Thoratec Corporation
Tianjin Medical
Olympus Corporation
Haemonetics Corporation
Some Recent Developments in the Cardiopulmonary Bypass System Market are:
In June 2014, Sorin Group celebrated the delivery of its 10,000th heart-lung machine (S5 heart-lung machine) to Brigham and Women’s Hospital, Boston, MA, USA. Thuse achieved an exciting milestone that reflects the tremendous trust and collaborative partnership with their customers worldwide.
In October 2021, MicroPort acquired 100% of the equity held by existing shareholders of Hemovent GmbH. Hemovent specializes in the development of ground-breaking Extracorporeal Life Support (ECLS) systems.
In February 2022, Getinge acquired 100% of the equity interest in Talis Clinical LLC, a US-based leading innovator of High Acuity cloud-based software solutions. Talis Clinical’s offer is designed to support and document care throughout the general and cardiac perioperative care process, but also through labor and delivery episodes and critical care support, including ECMO Therapy.
In April 2022, LivaNova initiated the targeted commercial launch of Essenz™. Patient Monitor for cardiopulmonary bypass procedures. The transformative monitoring system uses a patient-tailored approach to improve clinical efficiency and quality of patient care during cardiopulmonary bypass (CPB) procedures.
In January 2021, Eurosets announced the full commercial release (out of the USA) of its novel ECMOlife system for Extracorporeal Life Support (ECLS). ECMOlife expands Eurosets’ portfolio to temporarily support patients in different therapeutic areas, including Extracorporeal Membrane Oxygenation (ECMO) and Mechanical Circulatory Support (MCS).
Key Segments Profiled in the Cardiopulmonary Bypass System Industry Survey Report:
By Product Type:
Conventional
Mini
By Modality:
Standalone
Portable
By End User:
Hospitals
Ambulatory Surgical Centers
Cardiac Research Centers
By Region:
North America
Latin America
Asia Pacific
The Middle East and Africa
Europe
Global Focus on Improved Outcomes: Global Cardiopulmonary Bypass System Market
The cardiopulmonary bypass systems market is on track for substantial growth over the next decade. In 2018, the total net worth of cardiopulmonary bypass systems sold globally was estimated at USD 173.9 million. By 2023, this figure had risen to USD 197.3 million, with further projections indicating a steady increase.
According to recent forecasts, the global cardiopulmonary bypass system market is anticipated to reach USD 270.9 million by 2033. This growth trajectory represents a compound annual growth rate (CAGR) of 3.2% during the forecast period.
It is anticipated that the rising costs of treating serious illnesses, such as heart ailments, will result in a greater need for cardiopulmonary bypass equipment. It is anticipated, therefore, that the adverse effects of bypass surgery will impede the uptake of these devices. Conversely, it is expected that the rapid progress of technology and the increase in surgical procedures will propel market expansion and offer new opportunities to market players.
Your Insightful Report Sample With Your Work Email:
https://www.futuremarketinsights.com/reports/sample/rep-gb-5855
The rising prevalence of cardiovascular diseases, coupled with advancements in medical technology, is driving the demand for cardiopulmonary bypass systems. These systems play a critical role in cardiac surgeries, providing essential support to patients during procedures.
As the market continues to expand, healthcare providers and patients alike stand to benefit from improved access to innovative cardiopulmonary bypass technologies, ultimately leading to better patient outcomes and enhanced quality of care.
Supporting Heart Health: Cardiopulmonary Bypass Systems Play a Vital Role
The global cardiopulmonary bypass system market is experiencing continued growth, driven by the increasing need for effective tools in cardiac surgery. Cardiopulmonary bypass systems play a critical role in open-heart surgery by temporarily taking over the functions of the heart and lungs, allowing surgeons to operate on a still heart.
Market Growth Fueled by Multiple Factors:
Several factors are contributing to the growth of the cardiopulmonary bypass system market:
Increased Focus on Cardiac Care: Rising healthcare expenditure directed towards combating heart disease, a leading global health concern, is creating a greater demand for advanced cardiac surgical procedures.
Technological Advancements: The market is continuously evolving with the development of innovative bypass systems. Roller pumps, for example, are gaining traction due to their affordability, ease of use, and reliable flow management.
Expanding Surgical Needs: The growing number of lung transplant procedures, particularly en-bloc double-lung transplants, is driving the demand for cardiopulmonary bypass systems to support these complex surgeries.
Key Takeaways:
The global cardiopulmonary bypass system market is expected to reach US$270.9 million by 2033, reflecting a rise from US$197.3 million in 2023.
This growth is projected at a steady compound annual growth rate (CAGR) of 3.2% throughout the forecast period.
Rising healthcare spending on cardiac procedures and advancements in technology are key drivers for market expansion.
The Cardiopulmonary Bypass System Market:
Minnetronix Inc.
Transonic
MAQUET Holding B.V. & Co. KG.
Getinge AB
Terumo Corporation
MicroPort Scientific Corporation
Xenios AG
Nipro Corporation
Eurosets Srl
OriGen Biomedical
Thoratec Corporation
Tianjin Medical
Olympus Corporation
Haemonetics Corporation
Some Recent Developments in the Cardiopulmonary Bypass System Market are:
In June 2014, Sorin Group celebrated the delivery of its 10,000th heart-lung machine (S5 heart-lung machine) to Brigham and Women’s Hospital, Boston, MA, USA. Thuse achieved an exciting milestone that reflects the tremendous trust and collaborative partnership with their customers worldwide.
In October 2021, MicroPort acquired 100% of the equity held by existing shareholders of Hemovent GmbH. Hemovent specializes in the development of ground-breaking Extracorporeal Life Support (ECLS) systems.
In February 2022, Getinge acquired 100% of the equity interest in Talis Clinical LLC, a US-based leading innovator of High Acuity cloud-based software solutions. Talis Clinical’s offer is designed to support and document care throughout the general and cardiac perioperative care process, but also through labor and delivery episodes and critical care support, including ECMO Therapy.
In April 2022, LivaNova initiated the targeted commercial launch of Essenz™. Patient Monitor for cardiopulmonary bypass procedures. The transformative monitoring system uses a patient-tailored approach to improve clinical efficiency and quality of patient care during cardiopulmonary bypass (CPB) procedures.
In January 2021, Eurosets announced the full commercial release (out of the USA) of its novel ECMOlife system for Extracorporeal Life Support (ECLS). ECMOlife expands Eurosets’ portfolio to temporarily support patients in different therapeutic areas, including Extracorporeal Membrane Oxygenation (ECMO) and Mechanical Circulatory Support (MCS).
Key Segments Profiled in the Cardiopulmonary Bypass System Industry Survey Report:
By Product Type:
Conventional
Mini
By Modality:
Standalone
Portable
By End User:
Hospitals
Ambulatory Surgical Centers
Cardiac Research Centers
By Region:
North America
Latin America
Asia Pacific
The Middle East and Africa
Europe
English
French (Français)
Arabic
Portuguese (Português)
Deutsch
Turkish (Türk)
Dutch (Nederlands)
Italiano
Romaian (Română)
Português (Brasil)
Greek (Ελληνικά)
Russian (русский)